Suppliers / Shaoxing Jingxin Pharmaceutical

Shaoxing Jingxin Pharmaceutical

China Updated 9 July 2026

Shaoxing Jingxin Pharmaceutical is an API manufacturer based in China. It holds 7 active US drug master files and 12 valid CEPs across a filed portfolio of 9 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 24 May 2024 as NAI.

7
active US DMFs
12
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 24 May 2024 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Shangyu, China Not on file
China, China 3006305239

What they file, and where

Molecule Regulators Docs
Rosuvastatin EDQM, US FDA 5
Levetiracetam EDQM, US FDA 3
Simvastatin EDQM 3
Rivaroxaban EDQM, US FDA 2
Ticagrelor EDQM, US FDA 2
Apixaban US FDA 1
Brivaracetam US FDA 1
Enrofloxacin For Veterinary Use EDQM 1
Levofloxacin EDQM 1

Also appears on these molecule pages

Apixaban API Brivaracetam API Levetiracetam API Levofloxacin API Rivaroxaban API Rosuvastatin API Simvastatin API Ticagrelor API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
US FDA None 1

Questions about Shaoxing Jingxin Pharmaceutical

Does Shaoxing Jingxin Pharmaceutical hold a US DMF or a CEP?
Shaoxing Jingxin Pharmaceutical holds 7 active US drug master files and 12 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Shaoxing Jingxin Pharmaceutical FDA-registered?
One site operated by Shaoxing Jingxin Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Shaoxing Jingxin Pharmaceutical's last inspection go?
The most recent inspection on record closed on 24 May 2024 as NAI (No Action Indicated: nothing objectionable was found). 1 inspection is on file.
Where does Shaoxing Jingxin Pharmaceutical manufacture?
2 registered sites are on record, in China (Shangyu and China). Every site is listed on this page with the register it came from.
What does Shaoxing Jingxin Pharmaceutical make?
9 molecules are on record against Shaoxing Jingxin Pharmaceutical, including Rosuvastatin, Levetiracetam, Simvastatin and Rivaroxaban. Each links through to that molecule's full manufacturer list.
Which regulators recognise Shaoxing Jingxin Pharmaceutical's GMP?
Current GMP certificates are on record from MFDS (Korea) and US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Shaoxing Jingxin Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 24 May 2024.

Comparable suppliers

Dr Reddy's Laboratories shares 5 molecules Biocon shares 5 molecules Lee Pharma shares 5 molecules Hetero shares 4 molecules Alivus Life Sciences shares 4 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates